TL;DR
This study reveals significant differences in the tumor microenvironment of African American (AA) versus European American (EA) colon cancer (CC) patients, with AA patients exhibiting a less robust anti-tumor immune response. These disparities in immune cell composition and gene expression may explain the poorer survival outcomes observed in AA patients and suggest potential avenues for targeted therapies.
What Problem Does This Paper Address?
Colorectal cancer (CRC) disproportionately affects African Americans (AAs), who experience higher incidence and mortality rates compared to European Americans (EAs). While socioeconomic factors and access to care contribute, a significant portion of this survival disparity remains unexplained, suggesting underlying biological differences. Previous research has hinted at altered tumor biology and immune system involvement in these disparities, but the precise mechanisms remain unclear. This paper aims to dissect these differences by comparing the immunogenomic signatures of colon tumors from AA and EA patients to understand how the tumor microenvironment might contribute to racial disparities in CRC outcomes.
Methods
The researchers utilized data from The Cancer Genome Atlas (TCGA) for colon cancer (CC) patients with available race and survival data. They employed CIBERSORT, a computational method, to estimate the proportions of different immune cell types within tumor samples, effectively characterizing the "immune cellular fraction." This analysis allowed for a comparison of immune cell composition between AA and EA patients. Furthermore, they analyzed gene expression data to assess the profiles of immunoinhibitory and immunostimulatory genes, as well as major histocompatibility complex (MHC) genes. Statistical analyses included Kaplan-Meier curves for survival analysis, Cox proportional hazards models to adjust for covariates, and multivariable linear regression to associate immune cell fractions with race and other factors. Differential gene expression was identified using t-tests with Benjamini-Hochberg correction.
Datasets
The primary dataset used was from The Cancer Genome Atlas (TCGA) for colon cancer (CC) patients. This data was accessed through the National Cancer Institute Genomic Data Commons and integrated with clinical and genomic data from the cBioPortal for Cancer Genomics. The study identified 254 patients meeting inclusion criteria, with 58 being African American (AA) and 196 being European American (EA).
Key Insights and Ideas
- Immune Microenvironment Disparity: The most striking finding is the clear difference in the immune landscape within tumors of AA versus EA CC patients. This suggests that the body's own defense mechanisms are interacting differently with the tumors based on race.
- Less "Hot" Tumors in AA Patients: AA tumors appear to have a "cooler" immune environment, characterized by fewer macrophages and CD8+ T cells, which are crucial for directly attacking cancer cells. Conversely, EA tumors seem to have a more "inflamed" or "hot" immune environment.
- Pro-Tumorigenic Signatures in AA Tumors: The increased presence of B cells and specific macrophage subtypes (M1 phenotype reduced in AA tumors) in AA tumors, coupled with a decrease in certain immune-suppressing molecules in EA tumors, points towards a potentially more pro-tumorigenic immune environment in AA patients.
- Implications for Immunotherapy: The observed differences in immune cell populations and gene expression, particularly regarding immune checkpoint molecules and MHC presentation, could explain why some patients respond better to immunotherapies than others. This opens doors for personalized treatment strategies.
Key Results
- Survival Disparities: While overall survival (OS) did not differ significantly between AA and EA patients in this cohort, progression-free survival (PFS) was significantly worse for AA patients (log-rank p = 0.038). AA patients had a median PFS of 1678 days, while EA patients had not reached median PFS.
- Immune Cell Fractions: AA tumors showed a significantly greater proportion of B cells (p < 0.01) and a decreased proportion of macrophages (p < 0.01) and CD8+ T cells (p = 0.03) compared to EA tumors.
- Specific Cell Subsets: AA patients had more memory B cells and plasma cells, while EA patients had more activated NK cells. Pro-inflammatory M1 macrophages were reduced in AA tumors.
- Gene Expression Differences: AA tumors exhibited decreased expression of key immunoinhibitory genes like IDO1, PD-1, PD-L1, and LAG3, but increased expression of CD160. EA tumors showed a greater proportion of M1 macrophages, associated with a favorable immune response.
- MHC Expression: Reduced expression of MHC class I and II molecules was observed in AA CC tumors, which is critical for antigen presentation and T cell recognition.
Limitations and Future Work
The authors acknowledge that the TCGA dataset, while large, has a relatively small sample size for CC, particularly for AA patients, which increases the possibility of Type II errors. They also note the unavailability of certain crucial data points like microsatellite stability and granular patient-level socioeconomic and clinical data, which could influence survival. Future work should focus on larger, multi-center studies to validate these findings and explore the underlying mechanisms of these racial differences in tumor immune response, potentially through race-stratified investigations and imaging studies to better understand MHC expression on immune cells. The findings suggest that targeted therapeutic interventions based on these immune signatures could be a promising avenue for addressing racial disparities in colon cancer.
Summary updated